Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanreqing capsule for mild and common COVID-19
ChiCTR2200058676Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Tanreqing capsule + vitamin C with Placebo + vitamin C (2 arms). Primary endpoint: Improvement of major symptoms of COVID-19. Started Mar 2022; status: recruiting.
02
Drugs
tanreqing
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200058676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058676.